BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12644921)

  • 1. Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation.
    David-Neto E; Pereira Araujo LM; Sumita NM; Mendes ME; Ribeiro Castro MC; Alves CF; Kakehashi E; Romano P; Yagyu EM; Queiroga M; Nahas WC; Ianhez LE
    Pediatr Nephrol; 2003 Mar; 18(3):266-72. PubMed ID: 12644921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ; Rosenthal P; Bouw R; Leung M; Snell P; Mamelok RD
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
    Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.
    Ensom MH; Partovi N; Decarie D; Dumont RJ; Fradet G; Levy RD
    Ther Drug Monit; 2002 Apr; 24(2):310-4. PubMed ID: 11897977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
    J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients].
    Kuriata-Kordek M; Boratyńska M; Urbaniak J; Woźniak M; Patrzałek D; Szyber P; Klinger M
    Pol Merkur Lekarski; 2006 Aug; 21(122):161-3; discussion 164. PubMed ID: 17144102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.
    Weber LT; Shipkova M; Armstrong VW; Wagner N; Schütz E; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B
    Clin Chem; 2002 Mar; 48(3):517-25. PubMed ID: 11861442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation.
    Filler G; Foster J; Berard R; Mai I; Lepage N
    Transplant Proc; 2004 Jun; 36(5):1327-31. PubMed ID: 15251324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.
    Brunet M; Martorell J; Oppenheimer F; Vilardell J; Millán O; Carrillo M; Rojo I; Corbella J
    Transpl Int; 2000; 13 Suppl 1():S301-5. PubMed ID: 11112019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mycophenolic acid in kidney transplant recipients treated with a low dose (1 gram/day) of mycophenolate mofetil.
    Julasareekul W; Eiam-Ong S; Bejraputra O; Seublinvong T
    J Med Assoc Thai; 2003 Aug; 86(8):766-71. PubMed ID: 12948276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients.
    Nashan B; Saliba F; Durand F; Barcéna R; Herrero JI; Mentha G; Neuhaus P; Bowles M; Patch D; Bernardos A; Klempnauer J; Bouw R; Ives J; Mamelok R; McKay D; Truman M; Marotta P
    Liver Transpl; 2009 Feb; 15(2):136-47. PubMed ID: 19177449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of an abbreviated pharmacokinetic profile for the estimation of mycophenolic acid exposure in pediatric renal transplant recipients.
    Weber LT; Hoecker B; Armstrong VW; Oellerich M; Tönshoff B
    Ther Drug Monit; 2006 Oct; 28(5):623-31. PubMed ID: 17038876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.